<DOC>
	<DOC>NCT00526279</DOC>
	<brief_summary>To evaluate compliance and patients' satisfaction in mono and combination treatment of Candesartan cilexetil (Atacand)/ Candesartan cilexetil 16mg, hydrochlorothiazide 12.5mg (Atacand plus) in hypertension.</brief_summary>
	<brief_title>COmpliance and Efficacy in Mono and Combination Tablet Study ATacand/Atacand Plus</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<criteria>1. Patients who have consented to participation/data release in this study 2. Patients diagnosed with hypertension and prescribed with atacand/atacand plus by the physician based on clinical decision 1. Secondary hypertension requiring therapy other than antihypertensive medication 2. Patients not prescribed with atacand/atacand plus based on safety reasons or any other reason as determined by the physician 3. Women in pregnancy or lactation 4. Patients enrolled in any other studies</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Atacand/Atacand plus</keyword>
	<keyword>COMBAT</keyword>
	<keyword>Compliance</keyword>
	<keyword>Naturalistic</keyword>
	<keyword>Observational</keyword>
</DOC>